Join the Campaign

ACIP recommends LAIV for 2018-19 influenza season

Committee reverses prior recommendations, approval rests with CDC director

On February 21, CDC’s Advisory Committee on Immunization Practices (ACIP) voted to include the intranasal quadrivalent live attenuated influenza vaccine (LAIV; FluMist—MedImmune/AstraZeneca) in its recommendations for the 2018-19 influenza season. ACIP had recommended against using the vaccine this season and last season, citing concerns about its effectiveness after the vaccine provided poor protection against H1N1 in the 2013-14 and 2014-15 seasons.

Since then, the manufacturer has included a different strain of H1N1 in the vaccine, A/Slovenia. In trials of children between 2 and 4 years old, the manufacturer found that antibody response to the new H1N1 component rose fourfold in 23% of participants after the first dose and in 45% of participants after the second dose, suggesting that the new H1N1 component is more effective than the prior one, A/Bolivia.

Because there has been minimal H1N1 activity over the last two seasons, and because ACIP recommendations against using the vaccine have kept it largely unused in the U.S., the actual effectiveness of the current vaccine in the population is unknown. However, CDC researchers who analyzed prior studies of LAIV found no statistically significant difference between LAIV and inactive influenza vaccine in effectiveness against H3N2 and influenza B viruses.

The committee’s recommendations await approval by CDC acting director Anne Schuchat, MD (RADM, USPHS), and the final recommendations will appear in CDC’s Morbidity and Mortality Weekly Report.

 

Ad Position: 
Bottom Center Aligned
  • Join the Campaign
  • Take Action ALT Text
  • Get the facts ALT text
LATEST NEWS
October 17, 2017
October 17, 2017
APhA Executive Vice President and CEO Thomas E. Menighan, BSPharm, MBA, ScD (Hon), FAPhA, testified in a hearing about drug prices held by the...
Gag clauses, lack of provider status hinder cost-effective care, importation is no solution, APhA CEO says
MORE
August 14, 2017
August 14, 2017
Tennessee saw major provider status legislation take effect on July 1. “Pharmacists as Providers” (HB 405/SB 461) gives Tennessee pharmacists formal...
‘Pharmacists as providers’ legislation went into effect July 1
MORE
July 13, 2017
July 13, 2017
The Massachusetts Senate and House of Representatives health care committee held a hearing on legislation that would expand the scope of practice...
Hearing held last month included testimony from pharmacists and physicians
MORE
Advertisement